The challenges of providing renal replacement therapy in decompensated liver cirrhosis

Thomas A. Gonwa, Hani M. Wadei

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Development of renal failure requiring renal replacement therapy (RRT) in the cirrhotic patient is a devastating complication. Survival without RRT is less than 10% on average at 6 months. However, it is now appreciated that all renal failure in this group of patients is not due solely to hepatorenal syndrome, and the cause of the renal failure affects the prognosis. This paper reviews the prognosis depending on cause and points out the difficulty in making the correct diagnosis. Provision of RRT is difficult in this group of patients due to hypotension and coagulopathy which is highly prevalent. Survival with RRT is still poor with only 30-60% of patients surviving to liver transplant. Provision of RRT should be offered as a bridge to patients awaiting liver transplant or those undergoing liver transplant evaluation. Provision of long-term RRT is usually not indicated in other cirrhotic patients who develop a need for RRT except as a trial to see if renal function will return. The decision between intermittent hemodialysis or continuous renal replacement therapy (CRRT) is usually based on the clinical characteristics of the patient. Neither has been demonstrated to be superior to the other, although CRRT may be better tolerated in the unstable patient. CRRT is clearly indicated in cases of fulminant hepatic failure as it does not raise intracranial pressure. Provision of intraoperative CRRT during liver transplant may be indicated to help control volume and electrolytes in those patients presenting for liver transplant with renal failure. Newer extracorporeal support systems, such as extracorporeal albumin dialysis (MARS) and fractional plasma separation and adsorption with hemodialysis (Prometheus), have recently been developed to provide both renal and liver support in this group of patients. These are still considered experimental, although the MARS system has been utilized to treat patients with hepatorenal syndrome, and is available outside the United States.

Original languageEnglish (US)
Pages (from-to)144-148
Number of pages5
JournalBlood Purification
Volume33
Issue number1-3
DOIs
StatePublished - Mar 2012

Fingerprint

Renal Replacement Therapy
Liver Cirrhosis
Renal Insufficiency
Liver
Transplants
Hepatorenal Syndrome
Renal Dialysis
Kidney
Survival
Acute Liver Failure
Intracranial Pressure
Hypotension
Electrolytes
Adsorption
Albumins

Keywords

  • Liver cirrhosis
  • Renal failure
  • Renal replacement therapy

ASJC Scopus subject areas

  • Nephrology
  • Hematology

Cite this

The challenges of providing renal replacement therapy in decompensated liver cirrhosis. / Gonwa, Thomas A.; Wadei, Hani M.

In: Blood Purification, Vol. 33, No. 1-3, 03.2012, p. 144-148.

Research output: Contribution to journalArticle

Gonwa, Thomas A. ; Wadei, Hani M. / The challenges of providing renal replacement therapy in decompensated liver cirrhosis. In: Blood Purification. 2012 ; Vol. 33, No. 1-3. pp. 144-148.
@article{d4bf8278efc34f4da755f034e21ab670,
title = "The challenges of providing renal replacement therapy in decompensated liver cirrhosis",
abstract = "Development of renal failure requiring renal replacement therapy (RRT) in the cirrhotic patient is a devastating complication. Survival without RRT is less than 10{\%} on average at 6 months. However, it is now appreciated that all renal failure in this group of patients is not due solely to hepatorenal syndrome, and the cause of the renal failure affects the prognosis. This paper reviews the prognosis depending on cause and points out the difficulty in making the correct diagnosis. Provision of RRT is difficult in this group of patients due to hypotension and coagulopathy which is highly prevalent. Survival with RRT is still poor with only 30-60{\%} of patients surviving to liver transplant. Provision of RRT should be offered as a bridge to patients awaiting liver transplant or those undergoing liver transplant evaluation. Provision of long-term RRT is usually not indicated in other cirrhotic patients who develop a need for RRT except as a trial to see if renal function will return. The decision between intermittent hemodialysis or continuous renal replacement therapy (CRRT) is usually based on the clinical characteristics of the patient. Neither has been demonstrated to be superior to the other, although CRRT may be better tolerated in the unstable patient. CRRT is clearly indicated in cases of fulminant hepatic failure as it does not raise intracranial pressure. Provision of intraoperative CRRT during liver transplant may be indicated to help control volume and electrolytes in those patients presenting for liver transplant with renal failure. Newer extracorporeal support systems, such as extracorporeal albumin dialysis (MARS) and fractional plasma separation and adsorption with hemodialysis (Prometheus), have recently been developed to provide both renal and liver support in this group of patients. These are still considered experimental, although the MARS system has been utilized to treat patients with hepatorenal syndrome, and is available outside the United States.",
keywords = "Liver cirrhosis, Renal failure, Renal replacement therapy",
author = "Gonwa, {Thomas A.} and Wadei, {Hani M.}",
year = "2012",
month = "3",
doi = "10.1159/000334149",
language = "English (US)",
volume = "33",
pages = "144--148",
journal = "Blood Purification",
issn = "0253-5068",
publisher = "S. Karger AG",
number = "1-3",

}

TY - JOUR

T1 - The challenges of providing renal replacement therapy in decompensated liver cirrhosis

AU - Gonwa, Thomas A.

AU - Wadei, Hani M.

PY - 2012/3

Y1 - 2012/3

N2 - Development of renal failure requiring renal replacement therapy (RRT) in the cirrhotic patient is a devastating complication. Survival without RRT is less than 10% on average at 6 months. However, it is now appreciated that all renal failure in this group of patients is not due solely to hepatorenal syndrome, and the cause of the renal failure affects the prognosis. This paper reviews the prognosis depending on cause and points out the difficulty in making the correct diagnosis. Provision of RRT is difficult in this group of patients due to hypotension and coagulopathy which is highly prevalent. Survival with RRT is still poor with only 30-60% of patients surviving to liver transplant. Provision of RRT should be offered as a bridge to patients awaiting liver transplant or those undergoing liver transplant evaluation. Provision of long-term RRT is usually not indicated in other cirrhotic patients who develop a need for RRT except as a trial to see if renal function will return. The decision between intermittent hemodialysis or continuous renal replacement therapy (CRRT) is usually based on the clinical characteristics of the patient. Neither has been demonstrated to be superior to the other, although CRRT may be better tolerated in the unstable patient. CRRT is clearly indicated in cases of fulminant hepatic failure as it does not raise intracranial pressure. Provision of intraoperative CRRT during liver transplant may be indicated to help control volume and electrolytes in those patients presenting for liver transplant with renal failure. Newer extracorporeal support systems, such as extracorporeal albumin dialysis (MARS) and fractional plasma separation and adsorption with hemodialysis (Prometheus), have recently been developed to provide both renal and liver support in this group of patients. These are still considered experimental, although the MARS system has been utilized to treat patients with hepatorenal syndrome, and is available outside the United States.

AB - Development of renal failure requiring renal replacement therapy (RRT) in the cirrhotic patient is a devastating complication. Survival without RRT is less than 10% on average at 6 months. However, it is now appreciated that all renal failure in this group of patients is not due solely to hepatorenal syndrome, and the cause of the renal failure affects the prognosis. This paper reviews the prognosis depending on cause and points out the difficulty in making the correct diagnosis. Provision of RRT is difficult in this group of patients due to hypotension and coagulopathy which is highly prevalent. Survival with RRT is still poor with only 30-60% of patients surviving to liver transplant. Provision of RRT should be offered as a bridge to patients awaiting liver transplant or those undergoing liver transplant evaluation. Provision of long-term RRT is usually not indicated in other cirrhotic patients who develop a need for RRT except as a trial to see if renal function will return. The decision between intermittent hemodialysis or continuous renal replacement therapy (CRRT) is usually based on the clinical characteristics of the patient. Neither has been demonstrated to be superior to the other, although CRRT may be better tolerated in the unstable patient. CRRT is clearly indicated in cases of fulminant hepatic failure as it does not raise intracranial pressure. Provision of intraoperative CRRT during liver transplant may be indicated to help control volume and electrolytes in those patients presenting for liver transplant with renal failure. Newer extracorporeal support systems, such as extracorporeal albumin dialysis (MARS) and fractional plasma separation and adsorption with hemodialysis (Prometheus), have recently been developed to provide both renal and liver support in this group of patients. These are still considered experimental, although the MARS system has been utilized to treat patients with hepatorenal syndrome, and is available outside the United States.

KW - Liver cirrhosis

KW - Renal failure

KW - Renal replacement therapy

UR - http://www.scopus.com/inward/record.url?scp=84856059822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856059822&partnerID=8YFLogxK

U2 - 10.1159/000334149

DO - 10.1159/000334149

M3 - Article

C2 - 22269395

AN - SCOPUS:84856059822

VL - 33

SP - 144

EP - 148

JO - Blood Purification

JF - Blood Purification

SN - 0253-5068

IS - 1-3

ER -